Study Comparing a Pantoprazole Formulation to the Currently Marketed Tablet for GERD and Erosive Esophagitis

Completed · Phase 3

Conditions studied: Gastroesophageal Reflux, Esophagitis

In brief

The purpose of this study is to demonstrate pharmacodynamic comparability between the pantoprazole spheroid formulation and the marketed tablet formulation.

Key facts

Study ID

NCT00195208

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

97

Starts

2005-06-01

Expected to finish

2005-11-01

Last updated by the study team

2013-02-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• GERD and a history of Erosive Esophagitis documented by endoscopy
• H. pylori negative

You may not qualify if…

• Gastrointestinal conditions such as esophageal stricture, esophageal varices, previous vagotomy
• Achlorhydria

Where it is running

• Study site — Anaheim, California, United States
• Study site — Los Angeles, California, United States
• Study site — Orange, California, United States
• Study site — San Diego, California, United States
• Study site — Miami, Florida, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Oklahoma City, Oklahoma, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.